3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil

Jardim, Alvaro V.; Jardim, Dora V.; Chaves, Bruno Rasmussen; Steglich, Matheus; Ot’alora G., Marcela; Mithoefer, Michael C.; Silveira, Dartiu X. da; Tófoli, Luís F.; Ribeiro, Sidarta Tollendal Gomes; Matthews, Rebecca; Doblin, Rick; Schenberg, Eduardo E.

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil

Página do item simplificado Estatísticas

dc.contributor.author	Jardim, Alvaro V.
dc.contributor.author	Jardim, Dora V.
dc.contributor.author	Chaves, Bruno Rasmussen
dc.contributor.author	Steglich, Matheus
dc.contributor.author	Ot’alora G., Marcela
dc.contributor.author	Mithoefer, Michael C.
dc.contributor.author	Silveira, Dartiu X. da
dc.contributor.author	Tófoli, Luís F.
dc.contributor.author	Ribeiro, Sidarta Tollendal Gomes
dc.contributor.author	Matthews, Rebecca
dc.contributor.author	Doblin, Rick
dc.contributor.author	Schenberg, Eduardo E.
dc.date.accessioned	2020-07-23T13:44:27Z
dc.date.available	2020-07-23T13:44:27Z
dc.date.issued	2020-07-03
dc.description.resumo	Objective: To conduct Brazil’s first clinical trial employing 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), given its high prevalence resulting from epidemic violence. Methods: Of 60 volunteers, four matched the inclusion & exclusion criteria. Three patients with PTSD secondary to sexual abuse (diagnosed by the Structured Clinical Interview for DSM-IV and the Clinician Administered PTSD Scale for DSMV-4 [CAPS 4]) completed enrollment and treatment, following a standardized Multidisciplinary Association for Psychedelic Studies protocol consisting of 15 weekly therapy sessions: three with orally administered MDMA with concurrent psychotherapy and music, spaced approximately 1 month apart. CAPS-4 scores two months after the final MDMA session were the primary outcome. Results: No serious adverse events occurred. The most frequent adverse events were somatic pains and anguish. CAPS-4 reductions were always greater than 25 points. The final scores were 61, 27, and 8, down from baseline scores of 90, 78, and 72, respectively. All reductions were greater than 30%, which is indicative of clinically significant improvement. Secondary outcomes included lower Beck Depressive Inventory scores and higher Post-Traumatic Growth Inventory and Global Assessment of Functioning scores. Conclusions: Considering the current limitations in safe and efficacious treatments for PTSD and recent studies abroad with larger patient samples, MDMA-assisted psychotherapy could become a viable treatment in Brazil.	pt_BR
dc.identifier.citation	JARDIM, Alvaro V. et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil. Braz. J. Psychiatry, São Paulo, jul. 2020. https://doi.org/10.1590/1516-4446-2020-0980. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462020005020203&lng=en&nrm=iso. Acesso em: 23 jul. 2020.	pt_BR
dc.identifier.doi	10.1590/1516-4446-2020-0980
dc.identifier.uri	https://repositorio.ufrn.br/jspui/handle/123456789/29711
dc.language	en	pt_BR
dc.rights	Attribution-NonCommercial 3.0 Brazil	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc/3.0/br/	*
dc.subject	N-Methyl-3,4-methylenedioxyamphetamine	pt_BR
dc.subject	Stress disorders, post-traumatic	pt_BR
dc.subject	Psychotherapy	pt_BR
dc.subject	Sexual abuse	pt_BR
dc.subject	Psychedelics	pt_BR
dc.title	3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil	pt_BR
dc.type	article	pt_BR